Intracardiac drug delivery

• US 6,309,370 B1
• Filed: 02/05/1998
• Issued: 10/30/2001
• Est. Priority Date: 02/05/1998
• Status: Expired due to Term

• Current Assignee: Biosense, Inc. (Cardinal Health, Inc.)
• Original Assignee: Biosense, Inc. (Cardinal Health, Inc.)
• Inventors: Matcovitch, Avraham, Yaron, Uri, Haim, Shlomo Ben
• Primary Examiner(s): KENNEDY, SHARON E
• Application Number:
  US09/019,453
• Time in Patent Office: 1,363 Days
• Field of Search: 604/131, 604/134-137, 604/156, 604/157, 604/523, 604/21, 604/65-67, 607/120, 607/122, 600/508, 600/513
• US Class Current: 604/66
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61M 2025/0076 Unidirectional valves
• CPC Class Codes: A61M 2025/0089 Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 25/0075 Valve means
• CPC Class Codes: A61M 25/0082 Catheter tip comprising a tool
• CPC Class Codes: A61M 25/0084 being one or more injection needles

Abstract

Apparatus for intracardiac drug administration, including a catheter which is inserted into a chamber of the heart and brought into engagement with a site in the heart wall. The catheter includes at least one position sensor, which generates signals responsive to the position of the catheter within the heart, and a drug delivery device, which administers a desired dose of a therapeutic drug at the site determined responsive to the signals from the position sensor.

Claims

1. Apparatus for intracardiac drug administration, comprising a catheter which is inserted into a chamber of the heart and brought into engagement with a site in the heart wall, the catheter comprising:

at least one position sensor at a distal end of the catheter for determining position and orientation coordinates of the distal end of the catheter by generating signals responsive to the position of the distal end of the catheter within the heart; and

a drug delivery device, which administers a desired dose of a therapeutic drug at the site determined responsive to the signals from the position sensor.

2. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the therapeutic drug comprises a growth factor.

3. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the drug is contained in a slow-release matrix.

4. Apparatus according to claim 3, wherein the matrix comprises a solid capsule.

5. Apparatus according to claim 1, wherein the catheter comprises a contact sensor disposed on a distal surface of the catheter, which senses contact of the surface with the heart wall.

6. Apparatus according to claim 5, wherein the contact sensor comprises a pressure sensor.

7. Apparatus according to claim 1, wherein the position sensor comprises a magnetic position sensor, which generates signals responsive to an externally- applied magnetic field.

8. Apparatus according to claim 1, wherein the catheter comprises at least one physiological sensor, which generates signals indicative of the viability of heart tissue at the site.

9. Apparatus according to claim 8, wherein the at least one physiological sensor comprises an electrode.

10. Apparatus according to claim 8, further in combination with a therapeutic drug, wherein the apparatus generates a viability map of the heart based on the signals and administers the drug responsive thereto.

11. Apparatus according to claim 1, and comprising a radiation source for irradiation of the myocardial tissue, wherein the catheter comprises a waveguide, which communicates with the radiation source.

12. Apparatus according to claim 11, further in combination with a therapeutic drug, wherein the drug delivery device administers the drug into a channel produced in the tissue by the irradiation.

13. Apparatus according to claim 12, wherein the drug is a solid capsule.

14. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the drug delivery device comprises a hollow needle, which extends distally from the catheter and penetrates the heart tissue to deliver the drug dose.

15. Apparatus according to claim 14, wherein the needle has a helical shape.

16. Apparatus according to claim 15, wherein the needle is adapted to be fastened to the site in the heart wall by a rotational movement of the needle.

17. Apparatus according to claim 14, wherein the needle is retracted into the catheter before and after the drug dose is delivered.

18. Apparatus according to claim 17, wherein the needle extends from the catheter through an opening in the catheter, which opening is covered by a puncture seal.

19. Apparatus according to claim 18, wherein the drug delivery device comprises a displacement mechanism, which extends and retracts the needle.

20. Apparatus according to claim 19, wherein the displacement mechanism controls the distance by which the needle extends from the catheter, so as to administer the drug at a predetermined depth within the heart wall.

21. Apparatus according to claim 1, wherein the drug administration is controlled responsive to variations in the thickness of the heart wall at the site.

22. Apparatus according to claim 21, wherein the catheter comprises an ultrasound transducer, which generates signals indicative of the thickness of the heart wall.

23. Apparatus according to claim 21, wherein the drug delivery device is gated to administer the drug when the wall at a predetermined thickness.

24. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the therapeutic drug comprises a liquid compound.

25. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the therapeutic drug comprises a soluble compound.

26. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the therapeutic drug comprises a gene encoding a growth factor.

27. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the therapeutic drug comprises naked DNA.

28. Apparatus according to claim 27, further in combination with a therapeutic drug, wherein the therapeutic drug comprises plasmid DNA.

29. Apparatus according to claim 1, further in combination with a therapeutic drug, wherein the therapeutic drug comprises an adenoviral vector.

30. Apparatus according to claim 2, wherein the growth factor comprises a vascular endothelial growth factor (VEGF).

31. Apparatus according to claim 2, wherein the growth factor comprises a fibroblast growth factor (FGF).

32. Apparatus according to claim 4, wherein the matrix is a biocompatible polymeric matrix.

33. Apparatus according to claim 32, wherein the capsule also includes an auxiliary agent.

34. Apparatus according to claim 1, wherein said agent comprises heparin.

35. Apparatus according to claim 1, wherein said drug delivery device administers said therapeutic drug by a burst of pressure.

36. Apparatus according to claim 17, wherein said needle is retracted during insertion of said catheter into said heart.

37. Apparatus according to claim 5, wherein the position sensor is used to position a distal end of the catheter generally perpendicular to the site in the heart wall.

38. Apparatus according to claim 37, further comprising control circuitry for ensuring contact between the distal end of the catheter and the site in the heart wall.

39. Apparatus according to claim 1, wherein the at least one position sensor generates signals responsive to an externally-applied field.

40. Apparatus according to claim 39, wherein the at least one position sensor is a magnetic position sensor.

41. Apparatus for intracardiac drug administration, comprising a catheter which is inserted into a chamber of the heart and brought into engagement with a site in the heart wall, the catheter comprising:

at least one magnetic position sensor for determining position coordinates of the catheter by generating signals responsive to the position of the catheter within the heart; and

a drug delivery device, which administers a desired dose of a therapeutic drug at the site determined responsive to the signals from the position sensor.

42. Apparatus according to claim 41, wherein the magnetic position sensor generates signals responsive to an externally-applied field.

43. Apparatus for intracardiac drug administration, comprising a catheter which is inserted into a chamber of the heart and brought into engagement with a site in the heart wall, the catheter comprising:

at least one position sensor for determining position coordinates of the catheter by generating signals relating to the position of the catheter within the heart responsive to an externally-applied field; and

a drug delivery device, which administers a desired dose of a therapeutic drug at the site determined responsive to the signals from the position sensor.

44. Apparatus according to claim 43, wherein the at least one position sensor determines position and orientation coordinates.

45. Apparatus according to claim 44, wherein the at least one position sensor is a magnetic position sensor.

46. A method for intracardiac drug administration, comprising:

providing a catheter having at least one magnetic position sensor;

introducing the catheter into a chamber of the heart;

sensing position coordinates of the catheter with the magnetic position sensor;

positioning the catheter, using the coordinates, in engagement with the heart wall at a desired site; and

administering a therapeutic drug at the site using the catheter.

47. A method according to claim 46, including applying an externally-applied field.

48. A method according to claim 47, including applying an externally-applied magnetic field.

49. A method for intracardiac drug administration, comprising:

providing a catheter having at least one position sensor;

applying an externally-applied field;

introducing the catheter into a chamber of the heart;

sensing position coordinates of the catheter with the at least one position sensor responsive to the externally-applied field;

positioning the catheter, using the coordinates, in engagement with the heart wall at a desired site; and

administering a therapeutic drug at the site using the catheter.

50. A method according to claim 49, including sensing position and orientation coordinates of the catheter.

51. A method according to claim 50, including applying an externally-applied magnetic field.

52. A method for intracardiac drug administration, comprising:

providing a catheter having at least one position sensor at a distal end of the catheter;

introducing the catheter into a chamber of the heart;

sensing position and orientation coordinates of the distal end of the catheter with the at least one position sensor;

positioning the distal end of the catheter, using the position and orientation coordinates, in engagement with the heart wall at a desired site; and

administering a therapeutic drug at the site using the catheter.

53. A method according to claim 52, further comprising administering a growth factor at the site using the catheter.

54. A method according to claim 53, further comprising administering a fibroblast growth factor (FGF) at the site using the catheter.

55. A method according to claim 53, further comprising administering a vascular endothelial growth factor (VEGF) at the site using the catheter.

56. A method according to claim 53, further comprising administering a gene encoding the growth factor at the site using the catheter.

57. A method according to claim 52, wherein administering the therapeutic drug comprises injecting a slow-release preparation of the drug into the myocardium.

58. A method according to claim 57, wherein administering the slow-release preparation comprises administering a liquid.

59. A method according to claim 57, wherein administering the slow-release preparation comprises inserting a capsule containing the drug into the myocardium.

60. A method according to claim 52, and comprising irradiating the heart wall for engendering revascularization of the myocardium.

61. A method according to claim 60, wherein irradiating the heart wall comprises generating a channel in the myocardium, and wherein administering the therapeutic drug comprises inserting the drug into the channel.

62. A method according to claim 52, wherein positioning the catheter comprises verifying contact between the catheter and the heart wall by receiving signals generated by a contact sensor disposed on the catheter.

63. A method according to claim 52, and comprising receiving physiological signals from the heart, wherein administering the therapeutic drug comprises administering the drug responsive to the physiological signals.

64. A method according to claim 63, further comprising receiving mechano-physiological signals from the heart.

65. A method according to claim 63, further comprising receiving electrophysiological signals from the heart.

66. A method according to claim 63, wherein administering the therapeutic drug comprises administering the drug responsive to a measure of tissue viability determined from the physiological signals.

67. A method according to claim 66, wherein administering the therapeutic drug comprises administering the drug substantially only in ischemic but viable areas of the heart.

68. A method according to claim 66, wherein administering the therapeutic drug comprises administering the drug responsive to a map of tissue viability.

69. A method according to claim 52, further comprising orienting the catheter in a desired orientation relative to the heart wall responsive to the position and orientation coordinates.

70. A method according to claim 52, wherein positioning the catheter comprises positioning the catheter relative to a grid of points delineating a zone for drug administration on a geometrical map of the heart.

71. A method according to claim 70, and comprising marking sites on the map at which the drug has been administered.

72. A method according to claim 52, wherein administering the therapeutic drug comprises administering a liquid compound.

73. A method according to claim 52, wherein administering the therapeutic drug comprises administering a soluble compound.

74. A method according to claim 52, wherein administering the therapeutic drug comprises administering naked DNA.

75. A method according to claim 74, wherein administering the therapeutic drug comprises administering plasmid DNA.

76. A method according to claim 52, wherein administering the therapeutic drug comprises administering an adenoviral vector.

77. A method according to claim 59, further comprising inserting a capsule including a biocompatible polymeric matrix containing the drug into the myocardium.

78. A method according to claim 77, further comprising including an auxiliary agent in the capsule.

79. A method according to claim 78, further comprising including heparin in the capsule.

80. A method according to claim 52, further comprising administering said therapeutic drug by a burst of pressure.

81. A method according to claim 52, further comprising administering said therapeutic drug multiple times in said heart.

82. Method according to claim 62, wherein the catheter is positioned generally perpendicular to the desired site in the heart wall.

83. Method according to claim 82, including verifying contact between the catheter and the desired site in the heart wall through control circuitry.

84. A method according to claim 52, including applying an externally-applied field.

85. A method according to claim 84, including applying an externally-applied magnetic field.